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ABSTRACT
Objectives We investigated whether the timing of 
hospital admission is associated with the risk of mortality 
for patients with COVID-19 in England, and the factors 
associated with a longer interval between symptom onset 
and hospital admission.
Design Retrospective observational cohort study of data 
collected by the COVID-19 Hospitalisation in England 
Surveillance System (CHESS). Data were analysed using 
multivariate regression analysis.
Setting Acute hospital trusts in England that submit data 
to CHESS routinely.
Participants Of 14 150 patients included in CHESS 
until 13 May 2020, 401 lacked a confirmed diagnosis of 
COVID-19 and 7666 lacked a recorded date of symptom 
onset. This left 6083 individuals, of whom 15 were 
excluded because the time between symptom onset and 
hospital admission exceeded 3 months. The study cohort 
therefore comprised 6068 unique individuals.
Main outcome measures All- cause mortality during the 
study period.
Results Timing of hospital admission was an independent 
predictor of mortality following adjustment for age, sex, 
comorbidities, ethnicity and obesity. Each additional day 
between symptom onset and hospital admission was 
associated with a 1% increase in mortality risk (HR 1.01; 
p<0.005). Healthcare workers were most likely to have an 
increased interval between symptom onset and hospital 
admission, as were people from Black, Asian and minority 
ethnic (BAME) backgrounds, and patients with obesity.
Conclusion The timing of hospital admission is 
associated with mortality in patients with COVID-19. 
Healthcare workers and individuals from a BAME 
background are at greater risk of later admission, which 
may contribute to reports of poorer outcomes in these 
groups. Strategies to identify and admit patients with high- 
risk and those showing signs of deterioration in a timely 
way may reduce the consequent mortality from COVID-19, 
and should be explored.
BACKGROUND
On 31 December 2019, the WHO China 
country office was informed of 44 cases of 
pneumonia of unknown cause in Wuhan 
city, China.1 By 14 June 2020, more than 
7.8 million cases of COVID-19 disease caused 
by the SARS- CoV-2 had been reported across 
188 countries and regions, resulting in 
431 000 deaths.2
Throughout the early stages of the 
pandemic clinicians treating patients with 
COVID-19 reported that infected individ-
uals were tending to present later than 
expected to hospital services, with many 
profoundly hypoxic and requiring respira-
tory support soon after admission. This has 
been attributed to the phenomenon of ‘silent 
hypoxia’; in COVID-19 infection, oxygen 
levels may fall dangerously low without an 
individual becoming aware of this.3 Another 
reason for later presentation in the UK may 
have been the public’s desire to ‘protect the 
National Health Service (NHS)’,4 and also a 
tendency to stay away from hospitals because 
of concerns that there was a risk of coming 
into contact with the disease there.5 However, 
late presentation to hospital services delays 
the correction of hypoxia and the initiation 
of potentially life- saving treatments including 
respiratory support and dexamethasone.6
We hypothesised that later hospital admis-
sion may be associated with increased 
mortality. We also hypothesised that some 
patient groups may be more prone to later 
hospital admission, providing an opportunity 
to deliver interventions to those most at risk.
Strengths and limitations of this study
 ► We used all available data from a large observation-
al data set, and analysed this using two multivariate 
regression models. Our findings are internally con-
sistent and statistically and clinically significant.
 ► This research has several limitations. Of 13 749 pa-
tients with a confirmed diagnosis of COVID-19, only 
6083 could be included in the study, and the date of 
symptom onset was self- reported, rather than ob-
jectively verified.
 ► Our data are observational and should be interpret-
ed with caution; the results may have been influ-
enced by unmeasured confounders.
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Objectives
 ► To determine whether the timing of hospital admis-
sion is associated with mortality for patients diagnosed 
with COVID-19 infection.
 ► To identify the characteristics of patients with 
COVID-19 most at risk of later hospital admission.
METHODS
Study design
We completed a retrospective observational cohort 
study using data from the COVID-19 Hospitalisation in 
England Surveillance System (CHESS), established by 
Public Health England to collect routine data during the 
COVID-19 pandemic.
Setting
We included data collected by CHESS between 8 February 
and 13 April 2020. During this time, data returns were 
received from 94 of 152 (62%) of all acute hospital trusts 
in England.
Participants
Participants were individuals included in the CHESS 
database during the study period. We excluded patients 
without a confirmed diagnosis of COVID-19, those for 
whom the date of symptom onset was not recorded and 
those in whom the recorded date of symptom onset was 
more than 3 months before or after the date of hospital 
admission (on the assumption that a data entry error had 
occurred).
Variables
A set of 23 case- level variables were identified for each 
patient, as follows.
Demographic
Age; sex; obesity; ethnicity (White, Asian, Black, other) 
and healthcare worker.
Comorbidities
Respiratory; asthma; diabetes; cardiovascular; hyperten-
sion; renal; liver; immunosuppressive disease and immu-
nosuppressive treatment.
Timing of hospitalisation
The timing of hospitalisation was a continuous variable 
defined as the number of days between symptom onset 
and admission to hospital. Patients hospitalised before 
symptom onset were assumed to have been admitted for 
a reason other than COVID-19: either they were infected 
but asymptomatic on admission or they became infected 
while in hospital.
The primary outcome was all- cause mortality during 
the study follow- up period. Patients who remained in 
hospital at the end of the follow- up period (13 May 2020) 
were considered to be censored.
Sample size
This was a consecutive sample, using all available data.
Figure 1 Patients’ flow diagram. CHESS, COVID-19 Hospitalisation in England Surveillance System.
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Statistical methods
Two multivariate regression models were used to estimate 
the impact of admission timing on patient mortality risk, 
and identify the patient characteristics associated with 
later hospital admission. A Cox proportional hazards 
regression model using the 22 case- level variables was fit 
with the patients’ survival and follow- up time as outcomes. 
In addition, a binary logistic regression model was fit to 
infer the association between the 21 case- level variables 
(excluding the timing of hospital admission) with a 
binary indicator for a ‘delayed’ hospital admission. Here, 
a delayed hospital admission was defined using a binary 
indicator to indicate whether each patient’s hospital 
admission delay was greater than the population median 
delay.
RESULTS
A total of 14 150 patients with COVID-19 were included 
in the CHESS database between 8 February and 13 April 
2020. After applying the exclusion criteria, 6068 unique 
individuals were included in the final analysis (figure 1). 
Of these 6068 patients, 843 patients (14%) developed 
symptoms of COVID-19 while a hospital inpatient, 
whereas 5225 patients (86%) were admitted to hospital 
after exhibiting COVID-19 symptoms, with a mean 
interval of 4.6 days between symptom onset and hospital 
admission.
A comparison of the patients included in the final 
analysis and in the whole CHESS population is shown in 
table 1. In general, the analysis cohort appears represen-
tative of all those included in the CHESS database during 
this time period; however, there are some differences 
in obesity, White ethnicity and the number of recorded 
comorbidities.
The characteristics of the included patients, according 
to the timing of admission, are shown in table 2. Several 
differences are apparent. Patients admitted after exhib-
iting COVID-19 symptoms were younger, more likely to 
be obese and more likely to be from Black, Asian and 
minority ethnic (BAME) backgrounds.
Kaplan- Meier survival curves for the subcohorts of 
patients admitted to hospital after more than 1, 2 and 3 
weeks of exhibiting COVID-19 symptoms show a higher 
mortality risk than the overall population (figure 2, 
panels A- C). After adjusting for all covariates via the 
multivariate Cox regression model, the fitted coefficients 
indicate that later hospital admission is an independent 
and statistically significant predictor of mortality, with a 
hazard ratio (HR) of 1.01 (ie, a 1% elevation in mortality 
risk for each additional day between symptom onset and 
hospital admission, p<0.005; figure 3). Of particular 
note is the observation that being hospitalised before 
symptom onset (which implies that the patient developed 
COVID-19 while a hospital inpatient) is associated with a 
considerably reduced risk of mortality (HR 0.52; 95% CIs 
0.45 to 0.61).
The observed predictors of later hospitalisation were 
examined using odds ratios (ORs) based on the fitted 
logistic regression model, and are shown in figure 4. 
There is a striking association with later presentation 
among healthcare workers (OR 4.87; 95% CIs 3.31 to 
6.53). Obese individuals and those who from a BAME 
background were also more likely to present later to 
hospital services.
DISCUSSION
We have shown that later hospital admission is associated 
with an increased risk of mortality following infection with 
COVID-19. Later admission is a predictor of poor outcome 
even after adjustment for age, sex, ethnicity, obesity and 
comorbidities, and suggests that timely hospital admis-
sion could reduce mortality in selected individuals who 
are at high risk of complications or showing signs of dete-
rioration. We have also shown that certain characteristics 
Table 1 Comparison of the included cohort with all those 






Median age 66 years 65 years
Male sex 61% 60%
Obesity 12% 7%
White ethnicity 58% 46%
Asian ethnicity 6.6% 5.1%
Black ethnicity 19% 15%
Number of comorbidities 1.0 0.65
CHESS, COVID-19 Hospitalisation in England Surveillance System.
Table 2 Characteristics of the included patients, according to the timing of admission
Hospitalised before symptom onset Hospitalised after symptom onset All patients
Median age 79 years 64 years 68 years
Male sex 52% 62% 61%
White ethnicity 63% 57% 59%
Asian ethnicity 3% 7% 7%
Black ethnicity 1% 2% 2%
Number of comorbidities 1.0/patient 1.2/patient 1.0/patient
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are associated with later hospital admission, and identi-
fied several ‘at- risk’ groups to which specific interventions 
could be addressed.
Our findings support the hypothesis that earlier detec-
tion of deterioration and timely admission could reduce 
mortality, particularly as knowledge of the disease grows, 
and treatment modalities improve.6 7 It has been observed 
previously that early and intensive hospital intervention 
can improve outcomes in patients with COVID-19;8 
however, the mechanisms by which this occurs are not 
yet fully understood. Death in patients with COVID-19 is 
commonly caused by an unregulated immune response, 
sometimes described as a ‘cytokine storm’,9 however little 
is known about the cause and prevention of this phenom-
enon. Correction of hypoxia and physiological optimis-
ation is likely to play a part, and recent interest has also 
focused on steroids and anticoagulation to reduce inflam-
mation and the abnormal coagulation that occurs during 
severe COVID-19 disease.6 10 It is therefore not surprising 
that hospital admission is an effective treatment for 
serious COVID-19 infection, and in common with other 
effective treatments for communicable diseases,11 the 
earlier it is delivered the more effective it tends to be.
The role of timely hospital admission is further 
supported by our observation that those patients who 
developed symptoms of COVID-19 while a hospital 
inpatient had a significantly reduced mortality. This is 
supported by the findings of other observational research 
that found patients with nosocomial infection had a lower 
mortality than patients who acquired COVID-19 in the 
community.12
We found that healthcare workers are significantly 
more likely to experience later hospital admission, when 
compared with other patients with COVID-19. This is, 
perhaps, intuitive, since healthcare workers may wish to 
avoid being a ‘burden’ to their colleagues, making them 
particularly reluctant to use hospital services.13 We also 
observed a strong association with later admission among 
individuals from a BAME background, as well as those with 
obesity. Later presentation by people in these groups could 
be a factor in the excess mortality that has been reported 
in previous analyses,14–16 and this is further supported by 
research from the USA identifying that minority ethnic 
patients admitted with confirmed COVID-19 infection 
are more likely to present with increased disease severity 
on admission chest radiographs.17 Strategies designed to 
encourage individuals from these groups to seek help 
at an earlier stage may prove effective in reducing these 
disparities.
This study has several limitations. Of 13 749 patients 
with a confirmed diagnosis of COVID-19, 7666 (56%) had 
no recorded date of symptom onset, and the exclusion 
Figure 2 Kaplan- Meier survival curves for the subcohorts of patients admitted to hospital after more than 1 week (A), 2 weeks 
(B) and 3 weeks (C) of exhibiting COVID-19 symptoms.
Figure 3 Hazard ratios for mortality (based on a Cox proportional hazards regression model).
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of a further 15 patients with a date of symptom onset 
more than 3 months from hospital admission suggests 
weaknesses in the quality of the data recorded in CHESS. 
While the date of hospital admission was objectively verifi-
able, the date of symptom onset was self- reported and may 
have been subject to recall bias. We believe our findings 
are generalisable to adults diagnosed with COVID-19 and 
admitted to hospital; however, there were too few children 
in the sample to draw conclusions regarding the paedi-
atric population. The most significant weakness is the use 
of observational data which makes it possible that our 
findings were influenced by unmeasured confounders.
We have demonstrated an association between later 
hospital admission and subsequent mortality for patients 
diagnosed with COVID-19. However, for the majority of 
individuals, COVID-19 is a mild illness,18 and it would not 
be practical to admit all diagnosed cases. We therefore 
propose further studies to evaluate the effect of identi-
fying and monitoring high- risk patients in the commu-
nity following diagnosis. It has been suggested that home 
measurements of oxygen saturation, using a simple pulse 
oximeter, could detect ‘silent hypoxia’ at an early stage,7 
and early trials of this approach have been encouraging.19 
A policy of prompt hospital admission for those showing 
deterioration has the potential to improve outcomes and 
save lives. This should be combined with specific educa-
tion of the public and particularly those groups who may 
present later to hospital services.
CONCLUSION
We have demonstrated an independent association 
between the timing of hospital admission and subse-
quent mortality in patients diagnosed with COVID-19. 
Those at greatest risk of later hospital admission are 
healthcare workers, people with obesity and individuals 
from a BAME background, and this may be a factor in 
the poorer outcomes that have been reported in these 
patient groups. Strategies to identify and admit patients 
showing signs of deterioration in a timely way may reduce 
the consequent mortality from COVID-19, and should be 
explored further.
Figure 4 Predictors of later hospital admission.
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